Skip to content

Neurologic Deficits and Recovery in Chronic Subdural Hematoma

Neurologic Deficits and Recovery in Chronic Subdural Hematoma

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05900557
Enrollment
0
Registered
2023-06-12
Start date
2025-03-01
Completion date
2025-03-01
Last updated
2025-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Subdural Hematoma

Brief summary

Chronic subdural hematoma (cSDH) is one of the most common problems treated by neurosurgeons, particularly as the population ages. While often dismissed as a benign problem, it has become clear that cSDH is associated with worse long term functional and cognitive outcomes compared to matched controls. Though surgical techniques for treatment of cSDH are becoming more effective and safe, a persisting problem of fluctuating, stroke-like neurological deficits has re-emerged. Such deficits are not always directly related to hematoma mass effect and not always relieved with surgical decompression, but can result in prolonged hospital course, additional workup, and sometimes even additional invasive treatments. While the cause of such events is unknown, we recently documented for the first time that massive waves of spreading depolarization can occur in these patients and were closely linked to such neurologic deficits in some patients. In the current study, we plan to expand on these preliminary findings with rigorous, standardized application of post operative subdural electrocorticography monitoring, pioneered at our institution to detect SD. We also plan to build on our large retrospective analysis estimating the overall incidence of such deficits in cSDH patients by assessing multiple proposed risk factors for SD. In addition, for the first time, we will assess the short- and long-term consequences of cSDH and SD with detailed functional, cognitive, and headache related outcome measurement. These assessments are based on several remarkable cases we have observed with time-locked neurologic deterioration associated with recurrent SD. This study qualifies as a mechanistic clinical trial in that we will be prospectively assigning patients to the intervention of SD monitoring and assessing outcomes related to the occurrence of SD. This constitutes the application of a novel measure of brain signaling and assessing biomarkers of these physiologic processes of SD. These studies will provide critically needed information on this novel mechanism for neurologic deficits and worse outcomes after cSDH evacuation. Upon successful completion, we would identify a targetable mechanism for poor outcomes that occur commonly in patients with cSDH. This overall strategy offers the opportunity to radically improve the care of patients with cSDH by focusing on clinical trials of pharmacologic therapies for neurologic deficits in patients with cSDH.

Interventions

DIAGNOSTIC_TESTECoG monitoring

Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.

Sponsors

University of New Mexico
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Single arm study performing subdural ECoG monitoring to assess for presence or absence of spreading depolarization.

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* chronic/ subacute subdural hematoma deemed necessary for surgical evacuation, * Ability to consent or have LAR consent

Exclusion criteria

* emergent need for evacuation, * acute traumatic subdural hematoma, and * severe baseline disability (mRS\>2) (modified Rankin Scale)

Design outcomes

Primary

MeasureTime frameDescription
Post operative neurologic deterioration.1-5 daysIncidence of decline in Markwalder grading scale (0\[normal\]-4\[comatose\]) or Glasgow coma scale (3\[no response\] to 15\[normal\]) by one point.

Secondary

MeasureTime frameDescription
MoCA30day, 90 day, 180 dayMontreal Cognitive Assessment (1-30) 30 is the best
NIH toolbox cognitive battery30day, 90 day, 180 dayThe NIH Toolbox Cognitive Battery provides an overall summary score along with fluid and crystallized cognition summary scores.
eGOS30day, 90 day, 180 dayExtended Glasgow outcome scale 1(dead)- 8(upper good recovery)
TBI QOL30day, 90 day, 180 dayThe TBI-QOL consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life
Headache disability Index30day, 90 day, 180 dayThe Headache Disability Index (HDI) is a 27-item questionnaire.The first two questions asks the patient to identify the frequency (1 per month; more than 1 but less than 4 per month; more than 1 per week) and intensity (mild, moderate, severe) of their headache. The remaining questions evaluate quality of life issues to determine headache disability.
PROMIS 29 profile30day, 90 day, 180 dayThe PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026